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ABSTRACT
Squamous cell carcinoma of the skin (SCC) is the most frequent cancer in renal transplant
recipients. Conversion to mammalian target of rapamycin inhibitors after diagnosis of SCC
may reduce the incidence of recurrence of skin cancer. This retrospective study evaluated
the outcome of renal transplant recipients followed by the Renal Unit with posttransplant
diagnosis of SCC treated with conversion from calcineurin inhibitors (CNIs) to Everolimus
(EVR) associated with low-dose cyclosporine. Eleven patients developed SCC at a median
time from renal transplantation of 107 months (range 36–264). Five patients with
creatinine clearance (CCl) below 40 mL/min before conversion developed end stage renal
disease (two cases) or further deterioration of renal function (two cases); only one patient
in this group maintained a stable renal function. The remaining six patients with a CC1
greater than 40 mL/min and proteinuria below 0.8 g/24 hours maintained a stable renal
function after conversion to EVR at a median follow-up of 22 months (range 15–75).
Conversion from CNIs to EVR has been proven safe, effective, and associated with low
recurrence of SCC in patients with a CCl 40 mL/min. In the case of preexisting
deterioration of renal function or significant proteinuria, conversion to EVR should be
carefully evaluated.THE INCIDENCE OF nonmelanoma skin cancers(NMSC) increases with time after transplantation and
varies from 5% to 60% among different geographic areas
and according to the time after transplantation. Mamma-
lian target of rapamycin (m-TOR) signaling has an impor-
tant role in development of cancer and is a critical pathway
for several growth factors.1 Many clinical trials demon-
strated that m-TOR inhibitors (m-TORi) have been asso-
ciated with a reduced incidence of SCC particularly in
patients converted from a calcineurin inhibitors (CNI)
immunosuppressive regimen.
METHODS
We performed a retrospective study of patients who underwent
renal transplantation from 1995 to 2009 and who developed a
squamous cell carcinoma of the skin (SCC) in the posttransplant
period treated with conversion of the immunosuppressive regimen
to m-TORi with low dose of cyclosporine (CYA). The admission
history, medications administered, and laboratory data were re-
viewed from the medical records. Patients were stratified in two
0041-1345/12/$–see front matter
http://dx.doi.org/10.1016/j.transproceed.2012.06.035
1926groups (Table 1) according to renal function and proteinuria at the
time of conversion to Everolimus (EVR).
RESULTS
Eleven patients developed SCC at a median time from
renal transplantation of 107 months (range 36– 264). There
were 10 males and one female patient; the overall median
age at diagnosis of SCC was 60 years (range 51–70). The
histological diagnosis of SCC was performed after surgical
excision of the lesions. The immunosuppressive regimen at
diagnosis was CYA, mycophenolate mofetil (MMF), and
corticosteroids in all cases. In all patients, conversion to
EVR associated with low-dose CYA was performed after
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aCONVERSION TO M-TORI 1927minimization or withdrawal of MMF. Median follow-up
after conversion to EVR was 22 months (range 2–75). Six
patients at the time of conversion had a creatinine clear-
ance greater then 40 mL/min and proteinuria below 0.8 g/24
hours (group A). Five of these maintained a stable renal
function and proteinuria after conversion to EVR at a
median follow-up of 23 months (range 15–75). Only one
patient in this group presented a deterioration of renal
function due to acute kidney injury. Five patients at the
time of conversion to EVR had a creatinine clearance
below 40 mL/min and a proteinuria ranging from 0.4 to 3.5
g/24 hours (group B). Three developed end stage renal
disease due to chronic allograft nephropathy at a median
follow-up of 10 months (range 2–26) after conversion; one
of them also developed a significant increase of proteinuria
from baseline. Only two cases of recurrence of SCC was
observed in group A, and no recurrence was observed in
Table 1. Number of Patients With Any Squamous Cell
Carcinoma Stratified for Renal Function and Proteinuria at the
Time of Conversion to Everolimus
Group A Group B
Number of patients 6 5
GFR (mL/min) 40 40
Proteinuria (g/24 h) 0.8 0.4 3.5
Median follow-up after
conversion to
everolimus (mo)
23 (range 15–75) 10 (range 2–26)
SCC recurrence after
conversion to
Everolimus
2 0
GFR, glomerular filtration rate; SCC, squamous cell carcinoma of the skin.group B.DISCUSSION
Use of m-TORi in renal transplant recipients who develop
SCC allows reduction or elimination of CNI-based immu-
nosuppression. This study confirms that conversion to EVR
with minimization of CYA in patients with creatinine
clearance greater then 40 mL/min and low-grade protein-
uria (0.8 g/24 hours) is safe and effective and is associated
with low recurrence of SCC (only two cases of recurrence in
a cohort of patients with recognized aggressive SCC). In
fact this cohort of patients benefits from the antiprolifera-
tive and antiangiogenic actions of m-TORi with low risk of
deterioration of renal function as demonstrated in other
observational studies.2 Conversely, conversion to EVR in
patients with glomerular filtration ratio below 40 mL/min or
high-grade proteinuria may lead to further deterioration of
renal function. In such patients, the risk-benefit profile of
conversion to EVR should be carefully evaluated on a
case-by-case basis. A recent study demonstrated that a
particular immune phenotype characterized by greater than
35 peripheral FOXP3 regulatory T cells/L is significantly
ssociated with increased risk for new SCC development.3
This could be a new useful parameter to decide which
patients submit to conversion to EVR-based immunosup-
pressive treatment.
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